London, United Kingdom

Louise Elizabeth Donnelly


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 71(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Louise Elizabeth Donnelly: Innovator in Respiratory Disorder Treatments

Introduction

Louise Elizabeth Donnelly is a notable inventor based in London, GB. She has made significant contributions to the field of medicine, particularly in the treatment of inflammatory respiratory disorders. Her innovative approach has the potential to improve the quality of life for many individuals suffering from conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Latest Patents

Donnelly holds a patent for the "Administration of resveratrol to treat inflammatory respiratory disorders." This patent outlines a method for treating these disorders through the administration of resveratrol and its pharmacologically acceptable derivatives. The method emphasizes oral or pulmonary administration, providing a novel approach to managing respiratory conditions. The patent is a testament to her commitment to advancing medical treatments and improving patient outcomes. She has 1 patent to her name.

Career Highlights

Throughout her career, Louise has been associated with prestigious institutions such as the Imperial College of Science, Technology and Medicine and Imperial College Innovations Limited. Her work in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Donnelly has worked alongside Peter John Barnes, a prominent figure in respiratory medicine. Their collaboration has likely enhanced the development of innovative treatments and research in the field.

Conclusion

Louise Elizabeth Donnelly's contributions to the treatment of inflammatory respiratory disorders highlight her role as a pioneering inventor. Her work continues to inspire advancements in medical science and offers hope for improved therapies for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…